Qin Yu-Juan, Lin Tao-Yan, Lin Xiao-Lin, Liu Yu, Zhao Wen-Tao, Li Xiao-Yan, Lian Mei, Chen Heng-Wei, Li Yong-Long, Zhang Xiao-Ling, Xiao Dong, Jia Jun-Shuang, Sun Yan
Guangdong Provincial Key Laboratory of Cancer Immunotherapy Research and Guangzhou Key Laboratory of Tumor Immunology Research, Cancer Research Institute, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China.
Institute of Comparative Medicine & Laboratory Animal Center, Southern Medical University, Guangzhou 510515, China.
J Cancer. 2020 May 18;11(15):4397-4405. doi: 10.7150/jca.43459. eCollection 2020.
Although the roles and underlying mechanisms of other PDK family members (i.e., PDK1, PDK2 and PDK3) in tumor progression have been extensively investigated and are well understood, the functions and underlying molecular mechanisms of pyruvate dehydrogenase kinase 4 (PDK4) in the tumorigenesis and progression of various cancers [including hepatocellular carcinoma (HCC)] remain largely unknown. In this study, we examined the expression profile of PDK4 in HCC clinical tissue specimens and the roles of PDK4 in the proliferation, tumorigenicity, motility and invasion of HCC cells. The immunohistochemistry (IHC) and quantitative real-time PCR (qRT-PCR) results revealed that PDK4 was significantly downregulated in the cohort of HCC clinical specimens. Additionally, PDK4 protein was found in both the nucleus and cytoplasm of HCC cells based on an immunofluorescence (ICC) assay, and PDK4 protein was also found in the nucleus and cytoplasm of cancer cells contained in HCC clinical specimens based on IHC. The CCK-8 assay and cell colony formation assay demonstrated that stable depletion of endogenous PDK4 by lentivirus-mediated RNA interference (RNAi) markedly promoted the proliferation of HCC cell lines (i.e., BEL-7402 and BEL-7404 cells) in vitro, while PDK4 silencing significantly enhanced the tumorigenic ability of BEL-7404 cells in vivo. In addition to enhance proliferation and tumorigenesis induced by PDK4 silencing, additional studies demonstrated that knockdown of PDK4 led to increase migration and invasion of BEL-7402 and BEL-7404 cells in vitro. Taken together, these findings suggest that the loss of PDK4 expression contributes to HCC malignant progression.
尽管其他丙酮酸脱氢酶激酶(PDK)家族成员(即PDK1、PDK2和PDK3)在肿瘤进展中的作用和潜在机制已得到广泛研究且为人熟知,但丙酮酸脱氢酶激酶4(PDK4)在各种癌症(包括肝细胞癌(HCC))的发生和进展中的功能及潜在分子机制仍 largely未知。在本研究中,我们检测了PDK4在HCC临床组织标本中的表达谱以及PDK4在HCC细胞增殖、致瘤性、运动性和侵袭中的作用。免疫组织化学(IHC)和定量实时PCR(qRT-PCR)结果显示,在HCC临床标本队列中PDK4显著下调。此外,基于免疫荧光(ICC)分析,在HCC细胞的细胞核和细胞质中均发现了PDK4蛋白,基于IHC分析,在HCC临床标本中的癌细胞的细胞核和细胞质中也发现了PDK4蛋白。CCK-8分析和细胞集落形成分析表明,慢病毒介导的RNA干扰(RNAi)稳定敲低内源性PDK4可显著促进HCC细胞系(即BEL-7402和BEL-7404细胞)在体外的增殖,而沉默PDK4可显著增强BEL-7404细胞在体内的致瘤能力。除了增强由PDK4沉默诱导的增殖和致瘤性外,进一步研究表明,敲低PDK4会导致BEL-7402和BEL-7404细胞在体外的迁移和侵袭增加。综上所述,这些发现表明PDK4表达缺失促进了HCC的恶性进展。